Grabowski et al. performed both ligand-and structure-based VS using commercial databases of nearly six million compounds. The authors selected two well-characterised chemotypes of smallmolecule modulators to build their models -i) m1 proposed in previous work by Murgueitio et al. and (ii) CU-CPT22 and the other benzotropolones discovered by Yin et al. . They carried out docking, rescoring, and visual inspection analyses and selected the best hits for biological testing to confirm their ability to inhibit TLR2-mediated responses. The most active compound, a pyrogallol derivative named MMG-11 inhibited both TLR2/1 and TLR2/6 signalling. It also showed a higher potency than the previously discovered CU-CPT22. Additionally, in a subsequent paper , Grabowski et al. confirmed that the identified compound was also able to selectively inhibit TLR7 and TLR8 signalling. Encouraged by these results, they applied a computationally-guided synthesis approach to get an analogue of that compound which showed dual inhibition of TLR2/8. Also, in another work, Bermudez et al. explored the chemical space around the pyrogallol-containing antagonists to improve synthetic accessibility and chemical stability.